arrow
J

Júlio Maria Fonseca Chebli

Universidade Federal de Juiz de Fora
H指数:20
被引数:1,789

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and treatment-based risk stratification of opportunistic infections in patients with inflammatory bowel disease: an ambispective cohort study in Brazil

炎症性肠病患者机会性感染的发病率和基于治疗的风险分层:一项巴西前瞻-回顾性队列研究

2026-05-010
PRE
Fatigue and Associated Clinical Characteristics in Patients With Crohn's Disease in the State of Bahia, Brazil

克罗恩病患者中的疲劳及其相关临床特征——巴西巴伊亚州研究

2025-12-010
PRE
Fatigue and Associated Variables in Patients With Crohn's Disease Undergoing Pharmacological Treatment

克罗恩病患者在接受药物治疗期间疲劳及相关变量研究

2025-12-010
PRE
Real-World Comparative Effectiveness and Safety of Ustekinumab Versus Anti-TNF Agents as First- or Second-Line Biologics in Crohn's Disease: A Multicenter Observational Study

真实世界中,乌司木单抗相较于抗-TNF药物的作为克罗恩病的一线或二线生物制剂的疗效与安全性比较:一项多中心观察性研究

2025-12-010
PRE
Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study

维多珠单抗与英夫利昔单抗在未接受过生物治疗的溃疡性结肠炎患者中的临床有效性和安全性: 一项比较真实世界的多中心观察性研究

2025-10-010
OAAI
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

托法替尼治疗溃疡性结肠炎的巴西研究:一项关于有效性和安全性的多中心观察性研究

2025-03-180
OA
P1176 Low serum albumin levels are associated with higher colectomy rates in patients with moderate-to-severe ulcerative colitis on tofacitinib
2025-01-220
PRE
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
2024-12-010
OA
Impact of Obesity on the Course of Inflammatory Bowel Disease
2024-12-010
OA
Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction-A Prospective Trial
2023-06-193
OAAI
Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil
2021-06-213
OAAI